Madison Asset Management LLC significantly increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) during the third quarter, acquiring 12,366 shares. This strategic investment was valued at approximately $1.935 million, signaling confidence in the company's prospects. Concurrently, other institutional investors also made adjustments to their holdings in CRL shares, reflecting broader market interest. Financial analysts maintain a "Moderate Buy" rating for CRL, with an average price target set at $209.46. This target suggests a potential upside from current levels, reinforcing a positive outlook for the biopharmaceutical services provider. The institutional buying activity, coupled with favorable analyst sentiment, underscores a bullish perspective on Charles River Laboratories' future performance.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis